GSKGSK plc

NYSE gsk.com


$ 38.44 $ 0.25 (0.65 %)    

Wednesday, 03-Jul-2024 12:59:56 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 38.46
$ 38.17
$ 0.00 x 0
$ 38.45 x 200
$ 38.14 - $ 38.49
$ 32.12 - $ 45.80
1,349,530
na
82.92B
$ 0.52
$ 13.20
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-15b

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...

Core News & Articles

GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...

Core News & Articles

GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...

 jefferies-maintains-buy-on-gsk-raises-price-target-to-53

Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.

 heartburn-drug-zantac-litigation-gsk-and-other-pharma-giants-face-trial-over-cancer-claims

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to...

 gsk-issues-statement-regarding-the-zantac-ranitidine-litigation-has-reached-a-confidential-settlement-with-martin-gross-gsk-does-not-admit-any-liability-in-this-settlement

- Reuters

 cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-negative-for-gsk

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is app...

 why-is-moderna-stock-trading-lower-on-wednesday

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...

 sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-cvc

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

 uk-chooses-pfizer-over-gsk-for-multi-million-dose-rsv-vaccine-contract

Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement in...

Core News & Articles

GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a set...

 the-european-medicines-agency-has-accepted-gsks-application-to-expand-use-of-jemperli-dostarlimab-in-combination-with-standard-of-care-chemotherapy-carboplatin-and-paclitaxel-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer

 The EMA’s Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the ...

 japans-ministry-of-health-labor-and-welfare-has-approved-gsks-omjjara-momelotinib-for-the-treatment-of-myelofibrosis

https://www.gsk.com/en-gb/media/press-releases/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis/

 industry-groups-back-gsks-effort-to-halt-70000-lawsuits-associated-with-heartburn-drug-zantac-caused-cancer

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threat...

 analyst-projects-strong-growth-for-gsk-innoviva-partnered-respiratory-drugs

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma...

Core News & Articles

iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery a...

Core News & Articles

-Reuters

 gsk-states-scientific-consensus-finds-no-consistent-evidence-linking-zantac-ranitidine-to-cancer-no-settlement-or-payment-made-in-ms-kaszas-voluntary-dismissal

- Reuters

 us-fda-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-adults-aged-50-59-at-increased-risk

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1Clinical d...